ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
twitter youtube facebook linkedin iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • Featured Industry Events
  • ATTENDEE MAP & PHOTOS
  • Register Now
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • Featured Industry Events
  • ATTENDEE MAP & PHOTOS
  • Register Now
loading...
Home Targeted Therapies

Patient Comment on Mobocertinib for Exon 20

on: January 29, 2021In: Targeted Therapies
Patient Comment on Mobocertinib for Exon 20

Mobocertinib for Exon 20-Related Lung Cancer of Great Interest to Patients My brother Kevin, who founded the Exon 20 Group at ICAN with me in early 2017, started on mobocertinib […] Read more

Trastuzumab Deruxtecan Potential New Treatment Options for HER2+ NSCLC

on: January 29, 2021In: Targeted Therapies
Trastuzumab Deruxtecan Potential New Treatment Options for HER2+ NSCLC

The novel antibody drug conjugate trastuzumab deruxtecan (T-DXd) demonstrated clinically meaningful and promising efficacy in patients with HER2-mutated NSCLC, according to interim results of the DESTINY-Lung01 trial, presented as part […] Read more

Targeting KRAS in Lung Cancer: The Past, Present, and Future 

on: January 29, 2021In: Targeted Therapies
Targeting KRAS in Lung Cancer: The Past, Present, and Future 

Although RAS mutations constitute some of the most common genetic alterations in patients with adenocarcinomas, efforts to target the RAS oncoprotein have not proven fruitful, not only in NSCLC but […] Read more

Mobocertinib May Offer Effective, Safe Treatment in NSCLC with EGFR Exon 20 Insertion Mutation

Beth Fand Incollingo
on: January 26, 2021In: Targeted Therapies, WCLC 2020 Archive
Mobocertinib May Offer Effective, Safe Treatment in NSCLC with EGFR Exon 20 Insertion Mutation

With no approved treatments for advanced NSCLC with EGFR exon 20 insertion mutations, treatment is mainly limited to chemotherapy, as these cancers don’t respond to traditional tyrosine kinase inhibitors (TKIs). […] Read more

Follow IASLC on Twitter

Tweets by @IASLC

IASLC Logo
ILCN Editorial Group   IASLC.org

© 2022 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC

Privacy Policy